Roche Taps Compugen to Seek Non-SNP Markers for Drug Response | GenomeWeb
NEW YORK (GenomeWeb News) – Compugen and Roche have agreed to collaborate in an effort to search for biomarkers that could help predict patient responses to drugs aimed at treating rheumatoid arthritis, Compugen said Thursday.
 
Compugen will use its GeneVa database, which holds around 200,000 non-SNP genetic variations, to investigate DNA samples for markers that could predict response or non-response to selected drugs Roche intends to develop.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.